Acute Toxicity from Topical Cocaine for Epistaxis: Treatment with Labetalol.
BACKGROUND
Topical cocaine is sometimes used for the treatment of epistaxis, as it has both potent anesthetic and vasoconstrictive properties. Cocaine has unpredictable cardiovascular effects, such as sudden hypertension, tachycardia, coronary arterial vasoconstriction, and dysrhythmia.


METHODS
We report a case of acute iatrogenic cardiovascular toxicity from the use of topical cocaine in a 56-year-old man presenting to the Emergency Department with profound epistaxis. To prepare for cauterization and nasal packing, the patient received 4% topical cocaine-soaked nasal pledgets. He became hypertensive, tachypneic, tachycardic, and dysphoric immediately after administration. To directly counter these adverse hyperadrenergic effects, the patient was given 10 mg intravenous labetalol, a mixed β- and α-blocker. This instantly normalized his vital signs and adverse subjective effects. His epistaxis was successfully treated, and he was discharged 1 h later. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: We believe that emergency physicians should be aware of the unpredictable acute cardiovascular toxicity of topical cocaine. Labetalol represents an effective first-line treatment, which, unlike benzodiazepines, directly counters the pharmacologic effects of cocaine and has no respiratory or sedative side effects. Labetalol, with its mixed β/α-blocking properties, also mitigates the potential for "unopposed α-stimulation."
Department of Emergency Medicine, University of California Davis Medical Center, Sacramento, California.
John R
JR
Richards
Department of Emergency Medicine, University of California Davis Medical Center, Sacramento, California.
Erik G
EG
Laurin
Department of Emergency Medicine, University of California Davis Medical Center, Sacramento, California.
Nabil
N
Tabish
Department of Internal Medicine, Division of Cardiology, Texas Tech University Health Sciences Center, El Paso, Texas.
Richard A
RA
Lange
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D003042:Cocaine / Q000009:adverse effects* / Q000633:toxicity*; D004636:Emergency Service, Hospital / Q000458:organization & administration; D004844:Epistaxis / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007741:Labetalol / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013610:Tachycardia / Q000209:etiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D014662:Vasoconstrictor Agents; D003042:Cocaine; D007741:Labetalol
beta-blocker; cardiovascular; cocaine; epistaxis; labetalol; poisoning; toxicity; unopposed alpha